HIV cohort study comparing people on and off treatment
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study follows adults with HIV over time to compare different groups based on how stable their virus levels are. It may help researchers understand who can safely interrupt treatment and who should stay on it, and how immune health changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have HIV-1 (not HIV-2).
- You can sign written consent and agree to follow study rules.
- You are covered by French Social Security.
- You are not currently on HIV antiretroviral therapy if you’re in the stable “ALT” or “HIC” groups.
- For the “PTC” group: your viral load was high (>2000 copies/mL) before starting treatment, you started within early infection or later infection, and after stopping treatment your viral load stayed below 400 copies/mL for 12 months (with a small allowance for one brief “blip”).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how “GALIG” gene products affect the body’s internal recycling process (called autophagy) in people living with HIV. It may help researchers understand differences between people on HIV treatment, starting treatment, or not currently taking it.
This study looks at how the immune system and HIV behave in people on long-term HIV treatment (ART), using blood samples that will be stored for future tests for up to 20 years. It may help researchers understand how well treatment is controlling HIV and improve future care.
This international study looks at blood samples from people with HIV to find markers that predict whether someone can control the virus without medication. It involves four groups: natural controllers, people who controlled virus after stopping treatment in a study, non-controllers (whose virus returns), and people stable on ART.
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
This study tests how well researchers can track HIV-related health and immune changes over time by collecting blood and other samples. It may help you and your care team by creating detailed monitoring, even if your HIV diagnosis is new or still being evaluated.
Hear when a new HIV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.